EMA Grants Priority Medicine Status to CAR-T Therapy for Lupus

The European Medicines Agency has awarded PRIME designation to C-CAR168, an experimental CAR-T cell therapy. This recognition accelerates the development and review process for the treatment of severe autoimmune conditions like Systemic Lupus Erythematosus and Lupus Nephritis. It signifies a notable step forward for CAR-T therapies beyond oncology into autoimmune disease management.